Cancer Therapeutics CRC operates an innovative collaborative business model with leading internationally renowned research institutes and academic partners.
The Company draws on the world-class research reputation of its collaborative scientific partners and their expertise, including discovery capabilities that combine cutting-edge cancer biology and industrial style small molecule medicinal chemistry.
The Children’s Cancer Institute (CCI) is the only independent medical research institute in Australia devoted to research into the causes, prevention and cure of childhood cancer. Their research programs bring together recognised leaders in the field and focus on understanding childhood cancer and identifying a more targeted and individualised approach to diagnostics and treatment.
CSIRO Materials Science and Engineering delivers creative molecular technologies for biomaterials and regenerative medicine. Their Recombinant Protein Production & Purification and Biomolecular Interaction Facilities are integral components in CTx programs.
Griffith Institute for Drug Discovery (GRIDD) works on the molecular and cellular mechanisms of human diseases – cancer, infection and immunity, neglected diseases, neurological disease and stem cell biology.
Melbourne Health fosters research that enhances patient care, challenges clinical practice and promotes innovative health service delivery. The organisation has close collaborative partnerships with research organisations within the famous Parkville Precinct, as well as nationally and internationally, faciliatating the optimal translation of research into clinical practice and health policy.
Monash University is a world leader in cancer research. Its work covers the spectrum of cancer types, with particular strengths in lung, prostate, breast and colorectal cancers. The Centre for Drug Candidate Optimisation (CDCO) at the Monash Institute of Pharmaceutical Sciences provides invaluable ADME lead optimisation advice and support to many CTx projects.
The National Cancer Centre Singapore (NCCS) is one of Asia’s leading regional centres for the research and treatment of cancer. Focusing its research on cancers that are common among Asians, NCCS is firmly positioned at the interface of clinical cancer care and oncology research in order to translate advances from research into better standards of care in clinical oncology.
Peter MacCallum Cancer Centre incorporates a hospital and research institute solely dedicated to cancer treatment, research and education. The Peter Mac research cycle, where teams of researchers investigate cancer at the laboratory bench, in the clinic and at the patient bedside, is unique in cancer research in Australia.
The Walter + Eliza Hall Institute of Medical Research (WEHI) is the oldest medical research institute in Australia, whose research not only enables discoveries in medical biology that shape contemporary thinking and paradigms and enhance the understanding of disease, but also provides means to translate these discoveries into improvements in diagnosis, prevention and treatment.
Clinical Genomics is a privately held Australian biotechnology company developing next generation products for colorectal cancer diagnosis. Clinical Genomics currently holds a portfolio of more than 20 patents and patents pending, has offices and laboratories in both Australia and the USA, and operates as an FDA-registered and TGA-licensed manufacturer and a NATA-accredited laboratory.
SYNthesis Research Pty Ltd is a privately held Australian company specializing in medicinal chemistry, and headquartered in Melbourne.
CTxONE was the original managing company of the CRC (2007-2014). The company has been strategically evolved since 1 July 2014 to become a key commercialisation partner for assets from the CTx pipeline. In 2015 CTxONE was the recipient of significant funding from the Wellcome Trust to accelerate the PRMT5 inhibitor project and was the licensing partner for this asset through CRT UK to MSD. Contractual research collaborations with MSD to support the rapid development of the PRMT5 inhibitor project are also managed through CTxONE.
Clinical Trials Specialists
Cancer Trials Australia (CTA) is a clinical trial network spread across multiple sites whose strength lies in the collective technical and intellectual expertise of its members and the sharing of their resources.
Medicines Development Limited (MDL) is an independent not-for-profit global health company dedicated to the development of affordable medicines and vaccines. MDL has the development expertise to undertake all stages of regulatory-compliant drug and vaccine development and to capitalise on innovative solutions for discovery, development and delivery of medicines.
Health, Education and Advocacy
Cancer Council of Victoria is an independent not-for-profit organisation with an international reputation for their innovative work in cancer research, prevention and support.
INC Research Australia is a subsidiary of INC Research, a global CRO with oncology as a key therapeutic area within their business. Not only do they provide invaluable contributions towards the CTx initiative of changing clinical trials paradigms to allow the rapid advancement of new oncology drugs, but also they are involved in CTx education initiatives for clinicians to develop a greater understanding of drug discovery.
The Victorian Comprehensive Cancer Centre (VCCC) is an alliance of eight Victorian organisations committed to cancer control with the vision to save lives through the integration of cancer research, education and patient care. Through innovation and collaboration, the VCCC will drive the next generation of improvements in prevention, detection and cancer treatment.